Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
28. März 2022 11:00 ET
|
Krystal Biotech, Inc.
Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in...
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
26. März 2022 12:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results...
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
24. März 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief...
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
18. März 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present...
Krystal Biotech Announces Settlement with PeriphaGen, Inc.
15. März 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding...
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
28. Februar 2022 07:00 ET
|
Krystal Biotech, Inc.
Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H...
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
24. Februar 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief...
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
18. Januar 2022 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing...
Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
30. November 2021 20:15 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the...
Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
29. November 2021 16:20 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a...